
Civil Society Concerns Over US Health Service Plan To Give Exclusive Patent Rights To Sanofi
The United States National Institutes of Health’s decision to consider granting an exclusive licence on patents for a newly government-developed vaccine to Sanofi has prompted a strong reaction from civil society warning against potential high prices and requesting transparency in the process.






